World ADC Content Library

Welcome to the World ADC media hub. Here you will find exclusive insights from our expert speakers, past presentations and articles plus much more. 

Email if you submit for approval content that you wish to share.


Speaker Interview Cover

An Exclusive Speaker Interview With…

Daniel O’Connor, Chief Executive Officer, Ambrx Biopharma

Beacon Cover

The H1-2023 ADC Exclusive Landscape Preview

This exclusive preview will showcase some of the data available in this carefully curated review, including insights from the trial landscape, the drug landscape, and a glimpse of the ADC deals list that have happened in the first half of 2023.

By Beacon Intelligence ADC, Hanson Wade


CDMO's in the Preclinical ADC Space: A Benchmarking Study

Antibody-Drug Conjugates (ADC) have progressed a long way as a modality in recent times, culminating in a flurry of new drug approvals over the past couple of years. However, despite this progress, there is little in the public domain detailing how service providers are used in this space, particularly for assets at the preclinical stage where the announcement of partnerships is rare.

At Hanson Wade Intelligence, we sought to shed light on this under-represented area. We carried out a survey of 51 preclinical ADC developers, as well as carrying out in-depth interviews to support the sentiment uncovered in the survey.

So whether you are a developer, a service provider, or an observer of this space, this report will add to your understanding and provide some well-needed clarity to the preclinical ADC space. We uncover the major players, the importance of company size and molecule toxicity, and the traits that developers consider the most important when outsourcing their preclinical ADC assets.

By Hanson Wade Market Research

speaker interview screenshot

An Exclusive Speaker Interview With…

Radek Spisek, Chief Executive Officer, SOTIO


The Rise and Rise of mRNA

By the Medicine Maker, World ADC San Diego Media Partner



An Exclusive Speaker Interview With Byondis:

  • Ruud Coumans, Project Leader, Antibody-Drug Conjugates
  • Patrick Groothuis, Principal Scientist, In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetic
  • Evelyn Van Den Tweel, Project Leader, Clinical Development


An Exclusive Speaker Interview With:

Amy Peterson, Executive Vice President & Chief Development Officer, CytomX

2019 - 2020

ADC Magazine

ADC magazine

Goodwin Biotechnology Poster

goodwin poster

ADC London Post Event Report


Speaker Interview


Antibody Drug Conjugates Clinical E-Book

World ADC San Diego ADC Clinical Ebook

ADCs with two bundles of chelator groups of
radionuclides for theranostic applications


Assessing Phase 1 Interim Data of MORAb-202, a Folate Receptor Alpha-Targeted Antibody-Drug Conjugate

Toshimitsu Uenaka



2017 Post Event Report


Linker Design: Why so complex? – GNF

Bernhard Geierstanger


Clinical Development of ADCs: ARX788, a Her2-targeting ADC as an Example – Ambrx

Yong-jiang Hei, M.D., Ph.D.


Novel Warheads for Targeted Therapies of Cancer - pro-PBDs: from Design to Clinical Candidates

Iontcho R. Vlahov, PhD
VP of Discovery Chemistry
Endocyte, Inc., West Lafayette, IN, USA

ADC SD Social Card (1)